NYSE:AGNAllergan Stock Price, Forecast & News

Allergan's stock was trading at $185.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGN shares have decreased by 1.8% and is now trading at $182.20. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) issued its quarterly earnings data on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, beating analysts' consensus estimates of $4.57 by $0.65. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive return on equity of 9.82% and a negative net margin of 32.76%. The business's quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $4.29 EPS. View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Investors of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of 1.62%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its Board of Directors has approved a stock buyback program on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

15 brokerages have issued twelve-month target prices for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's share price to reach $180.08 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View analysts' price targets for Allergan.

Media headlines about AGN stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAllergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Metropolis Capital Ltd (0.06%), Alpine Global Management LLC (0.03%), State of Alaska Department of Revenue (0.02%), Clifford Swan Investment Counsel LLC (0.01%), Confluence Investment Management LLC (0.00%) and IBM Retirement Fund (0.00%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Matthew M Walsh and William Meury. View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Metropolis Capital Ltd, Fulton Bank N.A., Clifford Swan Investment Counsel LLC, Park National Corp OH, Simon Quick Advisors LLC, Peoples Financial Services CORP., and M&G Investment Management Ltd.. View insider buying and selling activity for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, State of Alaska Department of Revenue, and IBM Retirement Fund. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $182.20.

Allergan has a market capitalization of $59.94 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe. View additional information about Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]